Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairment

Efstathios Kastritis • 11 Dec 2021
ASH 2021
Multiple Myeloma Antibodies Daratumumab Dexamethasone

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses a prospective Phase II study which aimed to evaluate the safety and efficacy of daratumumab plus dexamethasone in patients with relapsed/refractory (R/R) myeloma with severe renal impairment or those undergoing dialysis. Dr Kastritis shares some results on the overall response rate and progression-free survival (PFS) observed in patients and the importance of these findings for this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.

More from Efstathios Kastritis

1:45
Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant
Efstathios Kastritis • 27 Sep 2023
2:14
Managing renal failure in patients with multiple myeloma
Efstathios Kastritis • 27 Sep 2023
1:04
Treatment approaches for AL amyloidosis versus ATTR amyloidosis
Efstathios Kastritis • 27 Sep 2023
1:30
AL amyloidosis: current and prospective treatments
Efstathios Kastritis • 10 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals